Medicaid, health care system confronting high cost of specialty drugs

Spending on specialty drugs for cancer, hepatitis and other conditions in Wisconsin’s Medicaid program is up 40 percent the past four years, a trend that could continue as more specialty drugs are approved, a state administrator said Thursday.